<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822859</url>
  </required_header>
  <id_info>
    <org_study_id>MCH NEB-1</org_study_id>
    <nct_id>NCT02822859</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Nebulizers for Standard Clinical and Research Use in Methacholine Challenge Testing</brief_title>
  <official_title>A Comparison of Three Nebulizers for Standard Clinical and Research Use in Methacholine Challenge Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess three different nebulizers for use in methacholine challenge testing in
      order to determine if the Aeroneb Solo would make a suitable replacement for the long-used
      and now obsolete Wright and Bennett-Twin nebulizers. Results from each device will be
      compared to evaluate whether current guidelines for the methacholine challenge should be
      updated for superior standardization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty asthmatics (20 at each testing site: University of Saskatchewan, McMaster University,
      Laval University) will be recruited to undergo this randomized, triple cross-over study.
      Three nebulizers will be tested, the Wright, the Bennett-Twin and the new Aeroneb Solo.

      Breakdown of study procedure: Participants will undergo three (potentially four) methacholine
      challenges, one with each nebulizer in randomized order. An additional methacholine challenge
      may be performed for screening purposes if the participant has not undergone methacholine
      challenge testing in one of the participating labs in the previous 6 months. The screening
      challenge will be performed with the standard nebulizer used at the given testing site (i.e.
      the Wright or the Bennett-Twin).

      The methacholine challenges performed with the Wright and Bennett-Twin nebulizers will follow
      the two-minute tidal breathing protocol as outlined in the 1999 American Thoracic Society
      Guidelines for Methacholine Challenge Testing. The testing protocol used with the Aeroneb
      solo will be identical save for a 1 min inhalation period instead of 2 min. Each challenge
      will be stopped when a participant's forced expiratory volume in 1 second (FEV1) drops at
      least 20%. This will allow for the determination of the participant's PC20 (provocative
      concentration of methacholine causing a 20% fall in FEV1), which will subsequently be
      converted to a PD20 (provocative dose) value. A minimum 24-hour washout period between
      challenges will be enforced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>airway responsiveness to methacholine (methacholine pd20)</measure>
    <time_frame>Two weeks</time_frame>
    <description>methacholine pd20 data will be compared between nebulizers (Wright, Bennett and Solo). Methacholine PD20 data generated with the Wright nebulizer will serve as the comparator for the methacholine pd20 generated with the Bennett and the Solo nebulizers.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Wright</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine challenge performed using the Wright nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bennett-Twin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine challenge performed using the Bennett-Twin nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aeroneb Solo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine challenge performed using the Aeroneb Solo nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wright nebulizer</intervention_name>
    <description>Roxon Medi-Tech, Montreal, QC, Canada</description>
    <arm_group_label>Wright</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bennett-Twin nebulizer</intervention_name>
    <description>Puritan Bennett Corp., Carlsbad, CA, USA</description>
    <arm_group_label>Bennett-Twin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aeroneb Solo</intervention_name>
    <description>Aerogen Ltd., Galway, Ireland</description>
    <arm_group_label>Aeroneb Solo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 or older

          -  Stable asthma

          -  Baseline methacholine PC20 less than or equal to 16mg/mL

          -  Baseline lung function greater than 65% predicted

        Exclusion Criteria:

          -  Use of long-acting bronchodilators within 30 days of Visit 1

          -  Pregnant or nursing

          -  Cardiovascular problems

          -  Respiratory illness within 4 weeks of Visit 1

          -  Allergen-induced asthma exacerbation within 4 weeks of Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Research Lab - University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Qu√©bec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Journal Publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

